Effects of alcohol, cigarettes, methamphetamine and marijuana exposure during pregnancy on maternal serum alpha-fetoprotein levels at 20-24 weeks’gestation
Journal of Pediatrics & Neonatal Care · 2018 · 8 (1)
DOI: 10.15406/jpnc.2018.08.00314 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pediatrics & Neonatal Care, 2018. Verfasst von HJ Odendaal. Die Arbeit wurde bisher 4-mal zitiert (Crossref).
Abstract (Originalsprache)
OBJECTIVE: To examine the effects of cigarette, marihuana and methamphetamine smoking and consumption of alcohol during pregnancy on maternal serum alpha-fetoprotein (MSAFP) levels at 20-24 weeks. STUDY DESIGN: In the Safe Passage Study (SPS) more than 12,000 pregnant women were prospectively followed up during pregnancy and until the infant was one year old to examine the effects of exposure to alcohol during pregnancy on stillbirth and sudden infant death syndrome. The present study is a cross-sectional secondary analysis of MSAFP analyses done at 20-24 weeks gestation in 1,679 SPS participants, recruited at the Bishop Lavis Community Health Centre, Cape Town, South Arica. RESULTS: ) or small mid upper arm circumference (MUAC) (
Zitieren
APA
Odendaal, H. (2018). Effects of alcohol, cigarettes, methamphetamine and marijuana exposure during pregnancy on maternal serum alpha-fetoprotein levels at 20-24 weeks’gestation. Journal of Pediatrics & Neonatal Care, 8(1). https://doi.org/10.15406/jpnc.2018.08.00314
Vancouver
Odendaal H. Effects of alcohol, cigarettes, methamphetamine and marijuana exposure during pregnancy on maternal serum alpha-fetoprotein levels at 20-24 weeks’gestation. Journal of Pediatrics & Neonatal Care. 2018;8(1). doi:10.15406/jpnc.2018.08.00314
BibTeX
@article{Odendaal2018,
author = {Odendaal, HJ},
title = {Effects of alcohol, cigarettes, methamphetamine and marijuana exposure during pregnancy on maternal serum alpha-fetoprotein levels at 20-24 weeks’gestation},
journal = {Journal of Pediatrics & Neonatal Care},
year = {2018},
volume = {8},
number = {1},
doi = {10.15406/jpnc.2018.08.00314}
}
EUVIMED